|
| 安罗替尼联合替吉奥二线后治疗晚期非小细胞肺癌的临床疗效 |
| Clinical efficacy of anlotinib combined with S-1 of advanced non-small cell lung cancer after second-line treatment |
| 投稿时间：2021-05-20 |
| DOI：10.3969/j.issn.1000-0399.2022.01.009 |
| 中文关键词: 晚期非小细胞肺癌 安罗替尼 替吉奥 |
| 英文关键词: Advanced non-small cell lung cancer Anlotinib S-1 |
| 基金项目:淮北市科技计划项目（项目编号：rj201818），白求恩·医学科学研究基金项目（项目编号：B19065ET） |
|
| 摘要点击次数: 1848 |
| 全文下载次数: 540 |
| 中文摘要: |
| 目的 探讨盐酸安罗替尼联合替吉奥二线后治疗晚期非小细胞肺癌的临床疗效及安全性。方法 选择2019年1月至2020年7月在淮北市人民医院就诊的70例至少接受过2种系统性治疗后进展或无法耐受的晚期非小细胞肺癌患者，采用随机数字表法，分为对照组（予以盐酸安罗替尼治疗）与试验组（予以盐酸安罗替尼联合替吉奥治疗），每组35例。对比两组患者治疗效果及不良反应情况的差异。结果 试验组患者客观缓解率为37.14%，疾病控制率为82.86%，均高于对照组（P<0.05）。试验组患者中位无进展生存期为7.3个月，高于对照组（P<0.05），但两组的中位总生存期差异无统计学意义（P>0.05）。试验组患者胃肠道反应（51.42%）、骨髓抑制（60.00%）、乏力（62.86%）等不良反应发生率高于对照组（P<0.05），其余不良反应大致相当（P>0.05）。两组患者不良反应均以Ⅰ~Ⅱ级为主，总体可控。结论 盐酸安罗替尼联合替吉奥二线后治疗晚期非小细胞肺癌疗效明显，安全性可控。 |
| 英文摘要: |
| Objective To investigate the clinical efficacy and safety of anlotinib hydrochloride combined with S-1 in the treatment of second-line advanced non-small cell lung cancer.Methods From January 2019 to July 2020, 70 patients with advanced non-small cell lung cancer who developed or could not tolerate after receiving at least two kinds of systematic treatment were selected from Huaibei People's Hospital. The 35 patients were randomly selected as the control groupand treated with anlotinib hydrochloride. The other 35 patients were set as the experimental group and treated with arotinib hydrochloride combined with S-1. The treatment effect and adverse reactions of the two groups were compared.Results The objective response rate(37.14%) and disease control rate(82.86%) of the experimental group were higher than those of the control group(P<0.05). The progression-free survival time(7.3 months) of the experimental group was higher than that of the control group(P<0.05), but there was no significant difference in the overall survival time between the two groups (P>0.05). The adverse reactions of the two groups were mainly grade Ⅰ~Ⅱ, but it could be controlled. The incidence of gastrointestinal reaction(51.42%), myelosuppression(60.00%) and fatigue (62.86%) in the experimental group was higher than that in the control group(P<0.05), and the other adverse reactions were similar(P>0.05).Conclusion The second-line treatment of advanced non-small cell lung cancer with anlotinib hydrochloride combined with S-1 is effective and safe. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
